Opinion: Pharma’s shift away from infectious disease research could spell disaster for the world’s poorest people
The number of “innovation champions” in the pharma industry working on infectious diseases is dropping — and that’s troubling, writes R&D director for Drugs for Neglected Diseases initiative.
